Advantages of nonhuman primates as preclinical models for evaluating stem cell-based therapies for Parkinson's disease

Stem Cell Research

Volumn 17, Issue 2, 2016, Pages 352-366

  Grow, Douglas A ^a   McCarrey, John R ^a   Navara, Christopher S ^a  

^a UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; IMMUNOGLOBULIN;

ACTION POTENTIAL; BABOON; DOPAMINE RELEASE; EFFERENT NERVE; HUMAN; IMMUNE SYSTEM; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PARKINSON DISEASE; PRECLINICAL STUDY; PREDICTION; PRIMATE; PRIORITY JOURNAL; REVIEW; REWARD; RODENT; SEQUENCE ANALYSIS; STEM CELL TRANSPLANTATION; ANIMAL; ANIMAL MODEL; BIOLOGICAL THERAPY; CYTOLOGY; DOPAMINERGIC NERVE CELL; INDUCED PLURIPOTENT STEM CELL; METABOLISM; STEM CELL; TRANSPLANTATION;

ACTION POTENTIALS; ANIMALS; CELL- AND TISSUE-BASED THERAPY; DOPAMINE; DOPAMINERGIC NEURONS; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MODELS, ANIMAL; PARKINSON DISEASE; STEM CELL TRANSPLANTATION; STEM CELLS;

EID: 84986573166     PISSN: 18735061     EISSN: 18767753     Source Type: Journal    
DOI: 10.1016/j.scr.2016.08.013     Document Type: Review

References (307)

1. Adams, E.J., Parham, P., Species-specific evolution of MHC class 1 genes in higher primates. Immunol. Rev. 183 (2001), 41–64.
2. Adams, E.J., Cooper, S., Thomson, G., Parham, P., Common chimpanzees have greater diversity than humans at two of the three highly polymorphic MHC class I genes. Immunogenetics, 51, 2000.
3. in Allen Mouse Brain Atlas. (2015).
4. Ansari, K.A., Johnson, A., Olfactory function in patients with Parkinson's disease. J. Chronic Dis. 28 (1975), 493–497.
5. Antunes, S.G., et al. The common marmoset a new world primate species with limited Mhc class II variability. Proc. Natl. Acad. Sci. U. S. A. 95 (1998), 11745–11750.
6. Araki, R., et al. Negligible immunogenicity of terminally differentiated cells derived from induced pluripotent or embryonic stem cells. Nature 494 (2013), 100–104.
7. Aron Badin, R., Vadori, M., Cozzi, E., Hantraye, P., Translational research for parkinsons disease: the value of pre-clinical primate models. Eur. J. Pharmacol. 759 (2015), 118–126.
8. Asquith, M., et al. Age-dependent changes in innate immune phenotype and function in rhesus macaques (Macaca mulatta). Pathobiol. Aging Age Relat. Dis., 2, 2012.
9. Attanasio, R., et al. Age-related autoanitbody production in a nonhuman primate model. Clin. Exp. Immunol. 123 (2001), 361–365.
10. Attanasio, R., Jayashankar, L., Engleman, C.N., Scinicariello, F., Baboon immunoglobulin constant region heavy chains: identification of four IGHG genes. Immunogenetics 54 (2002), 556–561.
11. Aurboonyawat, T., Suthipongchai, S., Pereira, V., Ozanne, A., Lasjaunias, P., Patterns of cranial venous system from the comparative anatomy in vertebrates part I, introduction and the dorsal venous system. Interv. Neuroradiol. 13 (2007), 335–344.
12. Bailey, M., Christoforidou, Z., Lewis, M.C., The evolutionary basis for differences between the immune systems of man, mouse, pig and ruminants. Vet. Immunol. Immunopathol. 152 (2013), 13–19.
13. Bannon, D., Landau, A.M., Doudet, D.J., How relevant are imaging findings in animal models of movement disorders to human disease?. Curr. Neurol. Neurosci. Rep., 15, 2015, 53.
14. Barcia, C., et al. Evidence of active microglia in substantia nigra pars compacta of parkinsonian monkeys 1 year after MPTP exposure. Glia 46 (2004), 402–409.
15. Bayer, H.M., Lau, B., Glimcher, P.W., Statistics of midbrain dopamine neuron spike trains in the awake primate. J. Neurophysiol. 98 (2007), 1428–1439.
16. Bernheimer, H., Birkmayer, W., Hornykiewicz, O., Jellinger, K., Seitelberger, F., Brain dopamine and the syndropmes of Parkinson and Huntington. J. Neurol. Sci. 20 (1973), 415–455.
17. Bezard, E., Imbert, C., Deloire, X., Bioulac, B., Gross, C.E., A chronic MPTP model reproucing the slow evolution of Parkinson's disease - evolution of motor symptoms in the monkey. Brain Res. 76 (1997), 107–112.
18. Bieger, D., Weerasuriya, A., Hockman, C.H., The emetic action of L-dopa and its effect on the swallowing reflex in the cat. J. Neural Transm. 42 (1977), 87–88.
19. Bjorklund, A., Dunnett, S.B., Dopamine neuron systems in the brain: an update. Trends Neurosci. 30 (2007), 194–202.
20. Björklund, A., Dunnett, S.B., Extrastriatal dopaminergic innervation of human basal ganglia. Trends Neurosci. 30 (2007), 194–202.
21. Bjorklund, A., Kordower, J.H., Cell therapy for Parkinson's disease: what next?. Mov. Disord. 28 (2013), 110–115.
22. Blin, J., Pappata, S., Kiyosawa, M., Crouzel, C., Baron, J.C., [18F]Setoperone: a new high-affinity ligand for positron emission tomography study of the serotonin-2 receptors in baboon brain in vivo. Eur. J. Pharmacol. 147 (1988), 73–82.
23. Boehmer, E.D., Goral, J., Faunce, D.E., Kovacs, E.J., Age-dependent decrease in toll-like receptor 4-mediated proinflammatory cytokine production and mitogen-activated protein kinase expression. J. Leukoc. Biol. 75 (2004), 342–349.
24. Bontrop, R.E., Watkins, D.I., MHC polymorphism: AIDS susceptibility in non-human primates. Trends Immunol. 26 (2005), 227–233.
25. Bove, J., Perier, C., Neurotoxin-based models of Parkinson's disease. Neuroscience 211 (2012), 51–76.
26. Boyson, J.E., et al. Evolution of a new nonclassical MHC class I locus in two old world primate species. Immunogenetics 49 (1999), 86–98.
27. Brischoux, F., Chakraborty, S., Brierley, D.I., Ungless, M.A., Phasic excitation of dopamine neurons in ventral VTA by noxious stimuli. Proc. Natl. Acad. Sci. U. S. A. 106 (2009), 4894–4899.
28. Brownell, A.-L., et al. Combined PET/MRS brain studies show dynamic and long-term physiological changes in a primate model of Parkinson disease. Nat. Med. 4 (1998), 1308–1312.
29. Brozoski, T.J., Brown, R.M., Rosvold, H.E., Goldman, P.S., Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 205 (1979), 929–932.
30. Bruhns, P., Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119 (2012), 5640–5649.
31. Brüünsgaard, H., Pedersen, B.K., Age-related inflammatory cytokines and disease. Immunol. Allergy Clin. N. Am. 23 (2003), 15–39.
32. Buus, S., Sette, A., Grey, H., The interaction between protein-derived immunogenic peptides and Ia. Immunol. Rev. 98 (1987), 115–141.
33. Caccone, A., Powell, J.R., DNA divergence among hominoids. Evolution 43 (1989), 925–942.
34. Cadavid, L.F., et al. Evolutionary instability of the major histocompatibility complex class I loci in new world primates. Proc. Natl. Acad. Sci. 94 (1997), 14536–14541.
35. Calabresi, P., Di Filippo, M., Ghiglieri, V., Tambasco, N., Picconi, B., Levodopa-induced dyskinesias in patients with Parkinson's disease: filling the bench-to-bedside gap. Lancet Neurol. 9 (2010), 1106–1117.
36. Calvas, P., et al. Characterization of the three immunoglobulin G subclasses of macaques. Scand. J. Immunol. 49 (1999), 595–610.
37. Carlsson, A., The occurrence distribution and physiological role of catecholamines in the nervous system. Pharmacol. Rev. 11 (1959), 490–493.
38. Chaudhuri, K.R., Quinn, N., What are the non-motor symptoms of Parkinson's disease?. Lancet Neurol. 5 (2006), 235–245.
39. Chaudhuri, K.R., Schapira, A.H., Non-motor symptoms of Parkinson's disease-dopaminergic pathophysiology and treatment. Lancet Neurol. 8 (2009), 464–474.
40. Cho, S.H., et al. SIRT1 deficiency in microglia contributes to cognitive decline in aging and neurodegeneration via epigenetic regulation of IL-1beta. J. Neurosci. 35 (2015), 807–818.
41. Christaki, E., Anyfanti, P., Opal, S.M., Immunomodulatory therapy for sepsis: an update. Expert Rev. Anti-Infect. Ther. 9 (2011), 1013–1033.
42. Chu, X., Bleasby, K., Evers, R., Species differences in drug transporters and implications for translating preclinical findings to humans. Expert Opin. Drug Metab. Toxicol. 9 (2013), 237–252.
43. Cohen, J., NIH to end chimp breeding for research. Science, 316, 2007, 1265.
44. Collins, P., Wilkinson, L.S., Everitt, B.J., Robbins, T.W., Roberts, A.C., The effect of dopamine depletion from the caudate nucleus of the common marmoset (Callithrix jacchus) on tests of prefrontal cognitive function. Behav. Neurosci. 114 (2000), 3–17.
45. Courtine, G., et al. Can experiments in nonhuman primates expedite the translation of treatments for spinal cord injury in humans?. Nat. Med. 13 (2007), 561–566.
46. Cox, L.A., et al. Baboons as a model to study genetics and epigenetics of human disease. ILAR J. 54 (2013), 106–121.
47. Cragg, S.J., Hille, C.J., Greenfield, S.A., Dopamine release and uptake dynamics within nonhuman primate striatum in vitro. J. Neurosci., 20, 2000, 8209.
48. D'Ambrosio, A.L., et al. A modified Transorbital baboon model of Reperfused stroke. Methods Enzymol., 200, 2000, 3054.
49. Damian, R.T., Greene, N.D., Kalter, S.S., IgG subclasses in the baboon (Papio cynocephalus). J. Immunol. 106 (1971), 246–257.
50. D'Ardenne, K., McClure, S.M., Nystrom, L.E., Cohen, J.D., BOLD responses reflecting dopaminergic signals in the human VTA. Science 319 (2008), 1264–1267.
51. Dauer, W., Przedborski, S., Parkinson's disease - mechanisms and models. Neuron 39 (2003), 889–909.
52. Dauer, W., et al. Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc. Natl. Acad. Sci. U. S. A. 99 (2002), 14524–14529.
53. Davie, C.A., A review of Parkinson's disease. Br. Med. Bull. 86 (2008), 109–127.
54. Davis, R., Huffman, R.D., Stereotaxic Atlas of the Baboon Brain. 1968, Southwest Foundation for Research Education, San Antonio, 160.
55. de Groot, N., et al. Major histocompatibility complex I diversity in west african chimpanzee population - implications for HIV research. Immunogenetics 51 (2000), 398–409.
56. de Groot, N.G., et al. Nomenclature report on the major histocompatibility complex genes and alleles of Great Ape, Old and New World monkey species. Immunogenetics 64 (2012), 615–631.
57. de Lange, G.G., Polymorphisms of human immunoglobulins: Gm, Am, Em and Km allotypes. Exp. Clin. Immunogenet. 6 (1989), 7–17.
58. Decamp, E., Schneider, J.S., Attention and executive function deficits in chronic low-dose MPTP-treated non-human primates. Eur. J. Neurosci. 20 (2004), 1371–1378.
59. Decressac, M., et al. GDNF fails to exert neuroprotection in a rat alpha-synuclein model of Parkinson's disease. Brain 134 (2011), 2302–2311.
60. Di Monte, D., et al. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model. Mov. Disord. 15 (2001), 459–466.
61. Diamond, A., Baddeley, A., Evidence for the importance of dopamine for prefrontal cortex functions early in life. Phil. Trans.: Biol. Sci. 351 (1996), 1483–1493.
62. Ding, Y.S., et al. Chiral drugs: comparison of the pharmacokinetics of [11C]d-threo and l-threo-methylphenidate in the human and baboon brain. Psychopharmacology 1997 (1997), 71–78.
63. Doerks, T., Copley, R.R., Schultz, J., Ponting, C.P., Bork, P., Systematic identification of novel protein domain families associated with nuclear functions. Genome Res. 12 (2002), 47–56.
64. Donahue, R.E., Dunbar, C.E., Update on the use of nonhuman primate models for preclinical testing of gene therapy approaches targeting hematopoietic cells. Hum. Gene Ther. 12 (2001), 607–617.
65. Drouot, X., et al. Functional recovery in a primate model of Parkinson's disease following motor cortex stimulation. Neuron 44 (2004), 769–778.
66. Dunn, T.B., et al. Revisiting traditional risk factors for rejection and graft loss after kidney transplantation. Am. J. Transplant. 11 (2011), 2132–2143.
67. Duong, T.Q., Diffusion tensor and perfusion MRI of non-human primates. Methods 50 (2010), 125–135.
68. Duzel, E., et al. Functional imaging of the human dopaminergic midbrain. Trends Neurosci. 32 (2009), 321–328.
69. Emborg, M.E., Nonhuman primate models of Parkinson's disease. ILAR J. 48 (2007), 339–355.
70. Emborg, M.E., et al. Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J. Comp. Neurol. 401 (1998), 253–265.
71. Emborg, M.E., et al. GDNF-secreting human neural progenitor cells increase tyrosine hydroxylase and VMAT2 expression in MPTP-treated cynomolgus monkeys. Cell Transplant. 17 (2008), 383–395.
72. Fagot, J., Paleressompoulle, D., Automatic testing of cognitive performance in baboons maintained in social groups. Behav. Res. Methods 41 (2009), 396–404.
73. Fagot, J., Thompson, R.K., Generalized relational matching by guinea baboons (Papio papio) in two-by-two-item analogy problems. Psychol. Sci. 22 (2011), 1304–1309.
74. Fahn, S., Parkinson's disease: 10 years of progress, 1997–2007. Mov. Disord. 25 (2010), S2–S14.
75. Fasano, A., Daniele, A., Albanese, A., Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation. Lancet Neurol. 11 (2012), 429–442.
76. Fernandez, R.C., Airborne transmission of Bordetella pertussis demonstrated in a baboon model of whooping cough. J. Infect. Dis. 206 (2012), 808–810.
77. Ferrari, E., et al. Age-related changes of the hypothalamic-pituitary-adrenal axis: pathophysiological correlates. Eur. J. Endocrinol. 144 (2001), 319–329.
78. Ferri, A.L., et al. Foxa1 and Foxa2 regulate multiple phases of midbrain dopaminergic neuron development in a dosage-dependent manner. Development 134 (2007), 2761–2769.
79. Ferro, M.M., et al. Comparison of bilaterally 6-OHDA- and MPTP-lesioned rats as models of the early phase of Parkinson's disease: histological, neurochemical, motor and memory alterations. J. Neurosci. Methods 148 (2005), 78–87.
80. Fifel, K., et al. Alteration of daily and circadian rhythms following dopamine depletion in MPTP treated non-human primates. PLoS One, 9, 2014, e86240.
81. Forno, L.S., Langston, W., Delanney, L.E., Irwin, I., Ricaurte, G.A., Locus ceruleus lesions and Eoxiophilic inclusions in MPTP-treated monkeys. Ann. Neurol. 20 (1986), 449–455.
82. Freed, C.R., et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N. Engl. J. Med. 344 (2001), 710–719.
83. Freed, C.R., Zhou, W., Breeze, R.E., Dopamine cell transplantation for Parkinson's disease: the importance of controlled clinical trials. Neurotherapeutics 8 (2011), 549–561.
84. Gaarder, P.I., Natvig, J.B., Distribution of isotypic and allotypic human IgG antigens in non-human primates. J. Immunol. 113 (1974), 635–655.
85. Gaillard, A., Jaber, M., Rewiring the brain with cell transplantation in Parkinson's disease. Trends Neurosci. 34 (2011), 124–133.
86. Gaillard, A., et al. Anatomical and functional reconstruction of the nigrostriatal pathway by intranigral transplants. Neurobiol. Dis. 35 (2009), 477–488.
87. Galvan, A., et al. Localization and function of dopamine receptors in the subthalamic nucleus of normal and parkinsonian monkeys. J. Neurophysiol. 112 (2014), 467–479.
88. Gelinas, D.S., McLaurin, J., PPAR-alpha expression inversely correlates with inflammatory cytokines IL-1beta and TNF-alpha in aging rats. Neurochem. Res. 30 (2005), 1369–1375.
89. German, D.C., Manaye, K.F., Brooksd, B.A., Midbrain dopaminergic cell loss in Parkinson's disease and MPTP-induced parkinsonism: sparing of calbindin-D28k-containing cells. Ann. N. Y. Acad. Sci. 648 (1992), 42–62.
90. Gloire, G., Legrand-Poels, S., Piette, J., NF-kappaB activation by reactive oxygen species: fifteen years later. Biochem. Pharmacol. 72 (2006), 1493–1505.
91. Goetz, C.G., et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 23 (2008), 2129–2170.
92. Goetz, C.G., Poewe, W., Rascol, O., Christina, S., The Unified Parkinson's Disease Rating Scale (UDPRS): status and recommendations. Mov. Disord. 18 (2003), 738–750.
93. Gonon, F.G., Nonlinear relationship between impulse flow and dopamine released by rat midbrain dopaminergic neurons as studied by in vivo electrochemistry. Neuroscience 24 (1988), 19–28.
94. R. Gonzalez et al., Proof of concept studies exploring the safety and functional activity of human parthenogenetic-derived neural stem cells for the treatment of Parkinson's disease. Cell Transplant. 34, 681 + 690 (2015).
95. Goujon, A., Fagot, J., Learning of spatial statistics in nonhuman primates: contextual cueing in baboons (Papio papio). Behav. Brain Res. 247 (2013), 101–109.
96. Grace, A.A., Phasic versus tonic dopamine release and the modulation of dopamine system responsivity - a hypothesis for the etiology of schizophrenia. Neuroscience 41 (1991), 1–24.
97. Grace, A.A., Bunney, B.S., The control of firing pattern in nigral dopamine neurons - burst firing. J. Neurosci., 11, 1984.
98. Grace, A.A., Bunney, B.S., The control of firing pattern in nigral dopamine neurons: single spike firing. J. Neurosci. 4 (1984), 2866–2876.
99. Grace, A.A., Onn, S.P., Morphology and electrophysiological properties of immunocytochemically identified rat dopamine neurons recorded in vitro. J. Neurosci. 9 (1989), 3463–3481.
100. Grainger, J., Dufau, S., Montant, M., Ziegler, J.C., Fagot, J., Orthographic processing in baboons (Papio papio). Science 336 (2012), 245–248.
101. Grealish, S., et al. The A9 dopamine neuron component in grafts of ventral mesencephalon is an important determinant for recovery of motor function in a rat model of Parkinson's disease. Brain 133 (2010), 482–495.
102. Grealish, S., et al. Human ESC-derived dopamine neurons show similar preclinical efficacy and potency to fetal neurons when grafted in a rat model of Parkinson's disease. Cell Stem Cell 15 (2014), 653–665.
103. Group, P.S., Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 287 (2002), 1653–1661.
104. Guha, P., Morgan, J.W., Mostoslavsky, G., Rodrigues, N.P., Boyd, A.S., Lack of immune response to differentiated cells derived from syngeneic induced pluripotent stem cells. Cell Stem Cell 12 (2013), 407–412.
105. Hadipour-Niktarash, A., Rommelfanger, K.S., Masilamoni, G.J., Smith, Y., Wichmann, T., Extrastriatal D2-like receptors modulate basal ganglia pathways in normal and parkinsonian monkeys. J. Neurophysiol. 107 (2012), 1500–1512.
106. Haley, P.J., Species differences in the structure and function of the immune system. Toxicology 188 (2003), 49–71.
107. Hallett, P.J., et al. Successful function of autologous iPSC-derived dopamine neurons following transplantation in a non-human primate model of Parkinson's disease. Cell Stem Cell 16 (2015), 269–274.
108. Hantraye, P., et al. Stable parkinsonian syndrome and uneven loss of striatal dopamine fibers following chronic MPTP administration in baboons. Neuroscience 53 (1993), 169–178.
109. Hantraye, P., et al. Inhibition of neuronal nitric oxide synthase prevents MPTP–induced parkinsonism in baboons. Nat. Med. 2 (1996), 1017–1021.
110. Hardman, C.D., et al. Comparison of the basal ganglia in rats, marmosets, macaques, baboons, and humans: volume and neuronal number for the output, internal relay, and striatal modulating nuclei. J. Comp. Neurol. 445 (2002), 238–255.
111. Hargus, G., et al. Differentiated Parkinson patient-derived induced pluripotent stem cells grow in the adult rodent brain and reduce motor asymmetry in parkinsonian rats. Proc. Natl. Acad. Sci. U. S. A. 107 (2010), 15921–15926.
112. Harris, T.B., et al. Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am. J. Med. 106 (1999), 506–512.
113. Hart, A.S., Rutledge, R.B., Glimcher, P.W., Phillips, P.E., Phasic dopamine release in the rat nucleus accumbens symmetrically encodes a reward prediction error term. J. Neurosci. 34 (2014), 698–704.
114. Hazeldine, J., Arlt, W., Lord, J.M., Dehydroepiandrosterone as a regulator of immune cell function. J. Steroid Biochem. Mol. Biol. 120 (2010), 127–136.
115. Heinbokel, T., Elkhal, A., Liu, G., Edtinger, K., Tullius, S.G., Immunosenescence and organ transplantation. Transplant. Rev. (Orlando) 27 (2013), 65–75.
116. Held, P.J., et al. The impact of HLA mismatches on the survival of first cadaveric kidney transplant. N. Engl. J. Med. 331 (1994), 765–770.
117. Hely, M.A., Reid, W.G., Adena, M.A., Halliday, G.M., Morris, J.G., The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov. Disord. 23 (2008), 837–844.
118. Herculano-Houzel, S., The human brain in numbers: a linearly scaled-up primate brain. Front. Hum. Neurosci., 3, 2009, 31.
119. Herculano-Houzel, S., Scaling of brain metabolism with a fixed energy budget per neuron: implications for neuronal activity, plasticity and evolution. PLoS One, 6, 2011, e17514.
120. Herrero, M.T., et al. Does neuromelanin contribute to the vulnerability of catecholaminergic neurons in monkeys intoxicated with MPTP. Neuroscience 1993 (1993), 499–511.
121. Hokfelt, T., Ungerstedt, U., Specificity of 6-hydroxydopamine induced degeneration of central monoamine neurones: an electron and fluorescence microscopic study with special reference to intracerebral injection on the nigro-striatal dopamine system. Brain Res. 60 (1973), 269–297.
122. Hong, S., Hikosaka, O., Pedunculopontine tegmental nucleus neurons provide reward, sensorimotor, and alerting signals to midbrain dopamine neurons. Neuroscience 282C (2014), 139–155.
123. Hornykiewicz, O., Biochemical aspects of Parkinson's disease. Neurology 51 (1998), S2–S9.
124. Hou, H., Wang, C., Jia, S., Hu, S., Tian, M., Brain dopaminergic system changes in drug addiction: a review of positron emission tomography findings. Neurosci. Bull. 30 (2014), 765–776.
125. Itakura, G., et al. Controlling immune rejection is a fail-safe system against potential tumorigenicity after human iPSC-derived neural stem cell transplantation. PLoS One, 10, 2015, e0116413.
126. James, I.M., Millar, R.A., Pruves, M.J., Observations on the extrinsic neural control of cerebral blood flow in the baboon. Circ. Res. XXV (1969), 77–94.
127. Jan, C., et al. Dopaminergic innervation of the pallidum in the normal state, in MPTP-treated monkeys and in parkinsonian patients. Eur. J. Neurosci., 12, 2000, 4525-4235.
128. Jarraya, B., et al. Dopamine gene therapy for Parkinson's disease in a nonhuman primate without associated dyskinesia. Sci. Transl. Med., 1, 2009, 2ra4.
129. Jensen, J., et al. Direct activation of the ventral striatum in anticipation of aversive stimuli. Neuron 40 (2003), 1251–1257.
130. Joel, D., Weiner, I., The connections of the dopaminergic system with the striatum in rats and primates: an analysis with respect to the functional and compartmental orgainization of the striatum. Neuroscience 96 (2000), 451–474.
131. Johannessen, J.N., Chiueh, C.C., Burns, R.S., Markey, S.P., Differences in the metabolism of MPTP in the rodent and primate parallel differences in sensitivity to its neurotoxic effects. Life Sci. 36 (1985), 219–224.
132. Jolly, C.J., Species, Species Concepts and Primate Evolution. 1993, Springer, 67–107.
133. Joyce, J.N., Janowsky, A., Neve, K.A., Characterization and distribution of [125]epidepride binding to dopamine D2 receptors in basal ganglia and cortex of human brain. J. Pharmacol. Exp. Ther. 257 (1991), 1253–1263.
134. Kaiser, J., NIH to phase out most chimp research. Science 341 (2013), 17–18.
135. Kaneko, S., Yamanaka, S., To be immunogenic, or not to be: that's the iPSC question. Cell Stem Cell 12 (2013), 385–386.
136. Kelley, J., Walter, L., Trowsdale, J., Comparative genomics of major histocompatibility complexes. Immunogenetics 56 (2005), 683–695.
137. Kennedy, R.C., Shearer, M.H., Hildebrand, W., Nonhuman primate models to evaluate vaccine safety and immunogenicity. Vaccine 15 (1997), 903–908.
138. Kim, K.S., Converting human skin cells to neurons: a new tool to study and treat brain disorders?. Cell Stem Cell 9 (2011), 179–181.
139. Kish, S.J., Shannak, K., Hornykiewicz, O., Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. N. Engl. J. Med. 318 (1988), 876–880.
140. Kleiner-Fisman, G., et al. Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced parkinsons diesease. J. Neurosurg. 99 (2003), 489–495.
141. Kowall, N., et al. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboon. Neuroreport 11 (2000), 211–213.
142. Kreutzber, G., Microglia: a sensor for pathological events in the CNS. Trends Neurosci. 19 (1996), 312–318.
143. Kriener, K., O'hUigin, C., Klein, J., Independent origin of functional MHC class II gened in humans and New World monkeys. Hum. Immunol. 2001 (2001), 1–14.
144. Kriks, S., et al. Dopamine neurons derived from human ES cells efficiently engraft in animal models of Parkinson's disease. Nature 480 (2011), 547–551.
145. Kruse, V., et al. Human induced pluripotent stem cells are targets for allogeneic and autologous natural killer (NK) cells and killing is partly mediated by the activating NK receptor DNAM-1. PLoS One, 10, 2015, e0125544.
146. Kumar, R., Lozano, A.M., Kim, Y.J., Hutchison, W.D., Sime, E., Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced parkinson's disease. Neurology 51 (1998), 850–855.
147. Kupsch, A., et al. Monoamine oxidase inhibition and MPTP-induced neurotoxicity in the non-human primate- comparison of rasagiline (TVP 1012) with selegiline. J. Neural Transm. 108 (2001), 985–1009.
148. Lafont, B.A.P., Buckler-White, A., Plishka, R., Buckler, C., Martin, M.A., Characterization of pig-tailed macaque classical MHC class I genes: implications for MHC evolution and antigen presentation in macaques. J. Immunol. 171 (2014), 875–885.
149. Laguna Goya, R., Tyers, P., Barker, R.A., The search for a curative cell therapy in Parkinson's disease. J. Neurol. Sci. 265 (2008), 32–42.
150. Laloux, C., et al. MPTP-treated mice: long-lasting loss of nigral TH-ir neurons but not paradoxical sleep alterations. Exp. Brain Res. 186 (2008), 635–642.
151. Lammel, S., Ion, D.I., Roeper, J., Malenka, R.C., Projection-specific modulation of dopamine neuron synapses by aversive and rewarding stimuli. Neuron 70 (2011), 855–862.
152. Langston, J.W., Mechanims of MPTP toxicity: more answers, more questions. Trends Pharmacol. Sci. 16 (1985), 375–378.
153. Langston, J., Ballard, P., Tetrud, J., Irwin, I., Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219 (1983), 979–980.
154. Langston, J.W., et al. Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine exposure. Ann. Neurol. 46 (1999), 598–605.
155. Lee, A.S., Tang, C., Rao, M.S., Weissman, I.L., Wu, J.C., Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat. Med. 19 (2013), 998–1004.
156. Lein, E.S., et al. Genome-wide atlas of gene expression in the adult mouse brain. Nature 445 (2007), 168–176.
157. Leist, M., Hartung, T., Inflammatory findings on species extrapolations: humans are definitely no 70-kg mice. Arch. Toxicol. 87 (2013), 563–567.
158. Leonard, C.M., et al. Size matters: cerebral volume influences sex differences in neuroanatomy. Cereb. Cortex 18 (2008), 2920–2931.
159. Lewis, D.A., Foote, S.L., Goldstein, M., Morrison, J.H., The dopaminergic innervation of monkey prefrontal cortex: a tyrosine hydroxylase immunohistochemical study. Brain Res., 449, 1988.
160. Li, X., et al. Allelic-dependent expression of an activating fc receptor on B cells enhances humoral immune responses. Sci. Transl. Med., 5, 2013, 216ra175.
161. Lindvall, O., Developing dopaminergic cell therapy for Parkinson's disease–give up or move forward?. Mov. Disord. 28 (2013), 268–273.
162. Lindvall, O., Barker, R.A., Brustle, O., Isacson, O., Svendsen, C.N., Clinical translation of stem cells in neurodegenerative disorders. Cell Stem Cell 10 (2012), 151–155.
163. Litvan, I., et al. Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. Mov. Disord. 27 (2012), 349–356.
164. Loas, G., Krystkowiak, P., Godefroy, O., Anhedonia in Parkinson's disease: an overview. J. Neuropsychiatr. Clin. Neurosci. 24 (2012), 444–451.
165. Lobb, C.J., Wilson, C.J., Paladini, C.A., High-frequency, short-latency disinhibition bursting of midbrain dopaminergic neurons. J. Neurophysiol. 105 (2011), 2501–2511.
166. Lynd-Balta, E., Haber, S.N., The organization of midbrain projections to the striatum in the primate: sensorimotor-related striatum versus ventral striatum. Neuroscience 59 (1994), 625–640.
167. M. G. S. Consortium, Initial sequencing and comparative analysis of the mouse genome. Nature 420 (2002), 520–562.
168. Magistris, M.T.D., et al. Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell 68 (1992), 625–634.
169. Mariani, E., et al. RANTES and MIP-1alpha production by T lymphocytes, monocytes and NK cells from nonagenarian subjects. Exp. Gerontol. 37 (2002), 219–226.
170. Mark Williams, S., Goldman-Rakic, P.S., Widespread origin of the primate mesofrontal dopamine system. Cereb. Cortex 8 (1998), 321–345.
171. Martin, L.N., Chromatographic fractionation of rhesus monkey (Macaca mulatta) IgG subcalsses using DEAE cellulose and protein A-sepharose. J. Immunol. Methods 50 (1982), 319–329.
172. Martin-Malivel, J., Fagot, J., Cross-modal integration and conceptual categorization in baboons. Behav. Brain Res. 122 (2001), 209–213.
173. Martins, P.N.A., et al. Age and immune response in organ transplantation. Transplantation 79 (2005), 127–132.
174. Mascarucci, P., et al. Age-related changes in cytokine production by leukocytes in rhesus monkeys. Aging 13 (2001), 85–94.
175. Matsumoto, M., Hikosaka, O., Two types of dopamine neuron distinctly convey positive and negative motivational signals. Nature 459 (2009), 837–841.
176. McCormack, A.L., et al. Aging of the nigrostriatal system in the squirrel monkey. J. Comp. Neurol. 471 (2004), 387–395.
177. McFarlane, D., Wolf, R.F., McDaniel, K.A., White, G.L., Age-associated alteration in innate immune response in captive baboons. J. Gerontol. A Biol. Sci. Med. Sci. 66 (2011), 1309–1317.
178. McHugh, P., Embryo ethics - the moral logic of stem-cell research. N. Engl. J. Med. 351 (2004), 207–209.
179. Medam, T., Fagot, J., Behavioral assessment of combinatorial semantics in baboons (papio papio). Behav. Process. 123 (2016), 54–62.
180. Meissner, W., et al. Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease. Mol. Neurobiol. 28 (2003), 209–218.
181. Mendez, I., et al. Cell type analysis of functional fetal dopamine cell suspension transplants in the striatum and substantia nigra of patients with Parkinson's disease. Brain 128 (2005), 1498–1510.
182. Merkel, T.J., Halperin, S.A., Nonhuman primate and human challenge models of pertussis. J. Infect. Dis. 209:Suppl 1 (2014), S20–S23.
183. Messaoudi, I., Estep, R., Robinson, B., Wong, S.W., Nonhuman primate models of human immunology. Antioxid. Redox Signal. 14 (2011), 261–273.
184. Mestas, J., Hughes, C.C.W., Of mice and not men: differences between mouse and human immunology. J. Immunol. 172 (2004), 2731–2738.
185. Michaelsen, T.E., Sandlie, I., Bratlie, D.B., Sandin, R.H., Ihle, O., Structural difference in the complement activation site of human IgG1 and IgG3. Scand. J. Immunol. 70 (2009), 553–564.
186. S. Mikula. (2013), vol. 2016.
187. Mizukami, Y., et al. MHC-matched induced pluripotent stem cells can attenuate cellular and humoral immune responses but are still susceptible to innate immunity in pigs. PLoS One, 9, 2014, e98319.
188. Moffett, A., Loke, C., Immunology of placentation in eutherian mammals. Nat. Rev. Immunol. 6 (2006), 584–594.
189. Moore, T.J., Glenmullen, J., Mattison, D.R., Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern. Med. 174 (2014), 1930–1933.
190. Morizane, A., et al. Direct comparison of autologous and allogeneic transplantation of iPSC-derived neural cells in the brain of a non-human primate. Stem Cell Rep. 1 (2013), 283–292.
191. Murray, A.M., Ryoo, H.L., Gurevich, E., Joyce, J.N., Localization of dopamine D3 receptors to mesolimbic and D2 receptors to mesostriatal regions of human forebrain. PNAS 91 (1994), 11271–11275.
192. Muthane, U., et al. Differences in nigral neuron number and sensitivity to 1-methyl-4-phenyl-1,2,3,6-tetrohydropyridine in C57-bl and CD-1 mice. Exp. Neurol. 126 (1994), 195–204.
193. Nair-Roberts, R.G., et al. Stereological estimates of dopaminergic, GABAergic and glutamatergic neurons in the ventral tegmental area, substantia nigra and retrorubral field in the rat. Neuroscience 152 (2008), 1024–1031.
194. Genome sequence of the Brown Norway rat yields insights into mammalian evolution. Nature, 428, 2004, 493–521.
195. Newman, T.K., Jolly, C.J., Rogers, J., Mitochondrial phylogeny and systematics of baboons (Papio). Am. J. Phys. Anthr. 124 (2004), 17–27.
196. Okamoto, Y., et al. Age-dependent decrease in serum transforming growth factor (TGF-1)-beta 1 in health japanese individuals - population study of serum TGF-beta 1 level in Japanese. Dis. Markers 21 (2005), 71–74.
197. Olanow, C.W., Kordower, J.H., Freeman, T.B., Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci. 19 (1996), 102–109.
198. Olanow, C.W., et al. A double-blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann. Neurol. 54 (2003), 403–414.
199. Orth, M., Tabrizi, S.J., Schapira, A.H.V., Cooper, J.M., α-Synuclein expression in HEK293 cells enhances the mitochondrial sensitivity to rotenone. Neurosci. Lett. 351 (2003), 29–32.
200. Otting, N., de Groot, N.G., Doxiadis, G.G., Bontrop, R.E., Extensive Mhc-DQB variation in humans and non-human primate species. Immunogenetics 54 (2002), 230–239.
201. Ovadia, A., Zhang, Z., Gash, D.M., Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys. Neurobiol. Aging 16 (1995), 931–937.
202. Parent, A., Lavoie, B., Smith, Y., Bédard, P., The dopaminergic nigropallidal projection in primates: distinct cellular origin and relative sparing in MPTP-treated monkeys. Adv. Neurol. 53 (1990), 111–116.
203. Parkinson, J., An Assay on the Shaking Palsy. 1817, Whittingham and Rowland.
204. Parkinson Study, G., Pramipexole vs levodopa as initial treatment for parkinson disease: a randomized controlled trial. JAMA 284 (2000), 1931–1938.
205. Parmar, M., Bjorklund, A., Generation of transplantable striatal projection neurons from human ESCs. Cell Stem Cell 10 (2012), 349–350.
206. Pessiglione, M., Seymour, B., Flandin, G., Dolan, R.J., Frith, C.D., Dopamine-dependent prediction errors underpin reward-seeking behaviour in humans. Nature 442 (2006), 1042–1045.
207. Pifl, C., Bertel, O., Schingnitz, G., Hornykiewicz, O., Extrastriatal dopamine in symptomatic and asymptomatic rhesus monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine - MPTP. Neurochem. Int. 17 (1990), 263–270.
208. Pignatelli, M., Bonci, A., Role of dopamine neurons in reward and aversion: a synaptic plasticity perspective. Neuron 86 (2015), 1145–1157.
209. Plackett, T.P., et al. Aging enhances lymphocyte cytokine defects after injury. FASEB J. 17 (2003), 688–689.
210. Poirier, N., et al. Advantages of Papio anubis for preclinical testing of immunotoxicity of candidate therapeutic antagonist antibodies targeting CD28. MAbs 6 (2014), 697–707.
211. Poirier, N., et al. Selective CD28 antagonist blunts memory immune responses and promotes long-term control of skin inflammation in nonhuman primates. J. Immunol. 196 (2016), 274–283.
212. Potts, L.F., et al. Modeling Parkinson's disease in monkeys for translational studies, a critical analysis. Exp. Neurol. 256 (2014), 133–143.
213. Prensa, L., Cossette, M., Parent, A., Dopaminergic innervation of human basal ganglia. J. Clin. Neuroanat. 20 (2000), 207–213.
214. Prillman, K., et al. Characterization of baboon class I major histocompatibility molecules implications for baboon-to-human xenotransplantation. Transplantation 61 (1995), 989–996.
215. Prillman, K., et al. Characterization of baboon class I major histocompatibility molecules: implications for baboon-to-human xenotransplantation. Transplantation 61 (1996), 989–996.
216. Ramayya, A.G., Zaghloul, K.A., Weidemann, C.T., Baltuch, G.H., Kahana, M.J., Electrophysiological evidence for functionally distinct neuronal populations in the human substantia nigra. Front. Hum. Neurosci., 8, 2014, 655.
217. Rammos, C., et al. Age-related vascular gene expression profiling in mice. Mech. Ageing Dev. 135 (2014), 15–23.
218. Renshaw, M., et al. Cutting edge: impaired Toll-like receptor expression and function in aging. J. Immunol. 169 (2002), 4697–4701.
219. Rhoades, E.R., Orne, I.M., Similar responses by macrophages from young and old mice infected with mycobacterium tubercolosis. Mech. Ageing Dev. 106 (1998), 145–153.
220. Rice, J., Animal models: not close enough. Nature, 484, 2012, S9.
221. Riederer, P., Wuketich, S., Time course of nigrostriatal degeneration in Parkninson's disease: a detailed study of influential factors in human brain amine analysis. J. Neural Transm. 38 (1976), 277–301.
222. Rink, L., Cakman, I., Kirchner, H., Altered cytokine production in the elderly. Mech. Ageing Dev. 102 (1998), 199–209.
223. Rizzari, M.D., Suszynski, T.M., Gillingham, K.J., Matas, A.J., Consideration of donor age and human leukocyte antigen matching in the setting of multiple potential living kidney donors. Transplantation 92 (2011), 70–75.
224. Robinson, J., et al. The IPD and IMGT/HLA database: allele variant databases. Nucleic Acids Res. 43 (2015), D423–D431.
225. Roeltgen, D.P., Schneider, J.S., Task persistence and learning ability in normal and chronic low dose MPTP-treated monkeys. Behav. Brain Res. 60 (1994), 115–124.
226. Roeper, J., Dissecting the diversity of midbrain dopamine neurons. Trends Neurosci. 36 (2013), 336–342.
227. Rogers, J., Hixson, J.E., Baboons as an animal model for genetic studies of common human disease. Am. J. Hum. Genet. 61 (1997), 489–493.
228. Rogers, J.D., Sanchez-Saffon, A., Frol, A.B., Diaz-Arrastia, R., Elevated plasma homocysteine levels in patients treated with levodopa. Arch. Neurol. 60 (2003), 59–64.
229. Rogers, J., et al. Heritability of brain volume, surface area, and shape: an MRI study in an extended pedigree of baboons. Hum. Brain Mapp. 28 (2007), 576–583.
230. Rose, S., et al. Age-related effects of 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine treatment of common marmosets. Eur. J. Pharmacol. 230 (1993), 177–185.
231. 2 fragments of monoclonal IgG of different rat IgG subclasses. J. Immunol. Methods 64 (1983), 141–146.
232. Rowley, M., Buchanan, H., Mackay, I., Reciprocal change with age in antibody to extrinsic and intrinsic antigens. Lancet 292 (1968), 24–26.
233. Salamone, J.D., et al. Tremulous jaw movements in rats: a model of parkinsonian tremor. Prog. Neurobiol. 56 (1998), 591–611.
234. Sanchez-Pernaute, R., et al. Parthenogenetic dopamine neurons from primate embryonic stem cells restore function in experimental Parkinson's disease. Brain 131 (2008), 2127–2139.
235. Sanger, G.J., Andrews, P.L., Treatment of nausea and vomiting: gaps in our knowledge. Auton. Neurosci. 129 (2006), 3–16.
236. Schapira, A.H., et al. Mitochondrial complex I deficiency in Parkinson's disease. Lancet, 333, 1989, 1269.
237. Schneider, J., Dacko, S., Relative sparing of the dopaminergic innervation of the globus pallidus in monkeys made hemi-parkinsonian by intracarotid MPTP infusion. Brain Res. 556 (1991), 292–296.
238. Schneider, J.S., Kovelowski, C.J., Chronic exposure to low doses of MPTP. I. Coginitive deficits in motor aymptomatic monkeys. Brain Res. 519 (1990), 122–128.
239. Schneider, J.S., Pope-Coleman, A., Cognitive deficits precede motor deficits in a slowly progressing model of parkinsonism in the monkey. Neurodegeneration 4 (1995), 245–255.
240. Schneider, J.S., Roeltgen, D.P., Delayed matching-to-sample, object retrieval, and discrimination reversal in chronic low dose MPTP-treated monkeys. Brain Res. 615 (1993), 351–354.
241. Schoenemann, P.T., Sheehan, M.J., Glotzer, L.D., Prefrontal white matter volume is disproportionately larger in humans than in other primates. Nat. Neurosci. 8 (2005), 242–252.
242. Schultz, W., Responses of midbrain dopamine neurons to behavioral trigger stimuli in the monkey. J. Neurophysiol. 56 (1986), 1439–1461.
243. Schultz, W., A neural substrate of prediction and reward. Science 275 (1997), 1593–1599.
244. Schultz, W., Predictive reward signal of dopamine neurons. J. Neurophysiol. 80 (1998), 1–27.
245. Schultz, W., Aebischer, P., The activity of pars compacta neurons of the monkey substantia nigra in relation to motor activation. Brain Res. 51 (1983), 377–387.
246. Scinicariello, F., Jayashankar, L., Attanasio, R., Baboon immunoglobulin variable region heavy chains: identification of genes homologous to members of the human IGHV1-IGHV7 subgroups. Immunogenetics 53 (2002), 815–820.
247. Sconce, M.D., Churchill, M.J., Greene, R.E., Meshul, C.K., Intervention with exercise restores motor deficits but not nigrostriatal loss in a progressive MPTP mouse model of Parkinson's disease. Neuroscience 299 (2015), 156–174.
248. Sedelis, M., Schwarting, R.K.W., Huston, J.P., Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav. Brain Res. 125 (2001), 109–125.
249. Sedelis, M., Schwarting, R.K.W., Huston, J.P., Behavioral phenotyping of the MPTP mouse model of Parkinson's disease. Behav. Brain Res. 125 (2001), 109–122.
250. Seniuk, N.A., Tatton, W.G., Greenwood, C.E., Dose-dependent destruction of coeruleus cortical and nigral-striatal projections by MPTP. Brain Res. 527 (1990), 7–20.
251. Seok, J., et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. U. S. A. 110 (2013), 3507–3512.
252. Seymour, B., et al. Temporal difference models describe higher-order learning in humans. Nature 429 (2004), 661–664.
253. Sharma, S., Deshmukh, R., Vinpocetine attenuates MPTP-induced motor deficit and biochemical abnormalities in Wistar rats. Neuroscience 286 (2015), 393–403.
254. Sharman, A., Hirji, R., Birmingham, J.T., Govind, C.K., Dopaminergic innervation of the subthalamic nucleus in the normal state, in MPTP-treated monkeys, and in Parkinson's disease patients. J. Comp. Neurol. 2000 (2000), 121–129.
255. Shearer, M.H., et al. The baboon as a nonhuman primate model for assessing the effects of maternal immunization with Haemophilus influenzae type b polysaccharide vaccines. Infect. Immun. 65 (1997), 3267–3270.
256. Shearer, M.H., et al. Comparison and characterization of immunoglubulin G subclasses among primate species. Clin. Vaccine Immunol. 6 (1999), 953–958.
257. Shearer, M.H., Dark, R.D., Chodosh, J., Kennedy, R.C., Comparison and characterization of immunoglobulin G subclasses among primate species. Clin. Vaccine Immunol. 6 (1999), 953–958.
258. Shiina, T., et al. Comparative genome analysis of the major histocompatibility complex (MHC) class I B/C segments in primates elucidated by genomic sequencing in common marmoset (Callithrix jacchus). Immunogenetics 63 (2011), 485–499.
259. Shimohama, S., Sawada, H., Kitamura, Y., Taniguchi, T., Disease model: Parkinson's disease. Trends Mol. Med. 9 (2003), 360–365.
260. Shinoyama, M., et al. Cortical region-specific engraftment of embryonic stem cell-derived neural progenitor cells restores axonal sprouting to a subcortical target and achieves motor functional recovery in a mouse model of neonatal hypoxic-ischemic brain injury. Front. Cell. Neurosci., 7, 2013, 128.
261. Shulman, L.M., Taback, R.L., Rabinstein, A.A., Weiner, W.J., Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat. Disord. 8 (2002), 193–197.
262. Sidebottom, D.A., Kennedy, R., Hildebrand, W.H., Class I MHC expression in the yellow baboon. J. Immunol. 166 (2001), 3983–3993.
263. Smith, Y., Lavoie, B., Dumas, J., Parent, A., Evidence for a distinct nigropallidal dopaminergic projection in the squirrel monkey. Brain Res. 482 (1989), 381–386.
264. Smith, R.D., Zhang, Z., Kurlan, R., McDermott, M., Gash, D.M., Developing a stable bilateral model of parkinsonism in rhesus monkeys. Neuroscience 52 (1992), 7–16.
265. Soldner, F., et al. Parkinson's disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 136 (2009), 964–977.
266. Soldner, F., et al. Generation of isogenic pluripotent stem cells differing exclusively at two early onset Parkinson point mutations. Cell 146 (2011), 318–331.
267. Stefani, A., et al. Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease. Brain 130 (2007), 1596–1607.
268. K. D. Sudheimer et al. (Michigan State University).
269. Sundberg, M., et al. Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and nonhuman primate iPSC-dervied dopaminergic neurons. Stem Cells 31 (2013), 1548–1562.
270. Suntharalingam, G., et al. Cytokine storm in phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N. Engl. J. Med. 355 (2006), 1018–1028.
271. Swift, M.E., Burns, A.L., Gray, K.L., DiPietro, L.A., Age-related alterations in the inflammatory response to dermal injury. J. Investig. Dermatol. 117 (2001), 1027–1035.
272. Syvanen, S., et al. Species differences in blood-brain barrier transport of three positron emission tomography radioligands with emphasis on P-glycoprotein transport. Drug Metab. Dispos. 37 (2009), 635–643.
273. Takahashi, K., et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131 (2007), 861–872.
274. Tanner, C.M., et al. Rotenone, paraquat, and Parkinson's disease. Environ. Health Perspect. 119 (2011), 866–872.
275. Tardif, S.D., Mansfield, K.G., Ratnam, R., Ross, C.N., Ziegler, T.E., The marmoset as a model of aging and age-related diseases. ILAR J. 52 (2011), 54–65.
276. Tarsy, D., Hurtig, H.I., Dashe, J.F., (eds.) UpToDate, 2015, Wolters Kluwer Health, Waltham, Massachussets.
277. Thomas, W.S., et al. Tissue factor contributes to microvascular defects after focal cerebral ischemia. Stroke 24 (1993), 847–853.
278. Thompson, L.H., Grealish, S., Kirik, D., Bjorklund, A., Reconstruction of the nigrostriatal dopamine pathway in the adult mouse brain. Eur. J. Neurosci. 30 (2009), 625–638.
279. Tullius, S.G., Milford, E., Kidney allocation and the aging immune response. N. Engl. J. Med. 364 (2015), 1369–1370.
280. Tuomela, S., Lahesmaa, R., Early T helper cell programming of gene expression in human. Semin. Immunol. 25 (2013), 282–290.
281. Ungerstedt, U., 6-Hydroxy-dopamine induced degeneration of central monamine neurons. Eur. J. Endocrinol. 5 (1968), 107–110.
282. Uylings, H.B.M., Groenewegen, H.J., Kolb, B., Do rats have a prefrontal cortex?. Behav. Brain Res. 146 (2003), 3–17.
283. van Schie, R.C., Wilson, M.E., Evaluation of human FcgammaRIIA (CD32) and FcgammaRIIIB (CD16) polymorphisms in Caucasians and African-Americans using salivary DNA. Clin. Diagn. Lab. Immunol. 7 (2000), 676–681.
284. Varastet, M., Riche, D., Maziere, M., Hantraye, P., Chronic MPTP treatment reproduces in baboons the differential vulnerability of mesencephalic dopaminergic neurons observed in parkinson's disease. Neuroscience 63 (1994), 47–56.
285. Viallet, F., Trouche, E., Beaubaton, D., Nieoullon, A., Legallet, E., Bradykinesia following unilateral lesions restricted to the nigra in the baboon. Neurosci. Lett. 24 (1981), 97–102.
286. Villemagne, V., et al. Brain dopamine neurotoxicity in baboons treated with doses of methamphetamine comparable to those recreationally abused by humans: evidence from [11C]WIN-35428 positron emission tomography studies and direct in vitro determinations. J. Neurosci. 18 (1998), 419–427.
287. Viray, J., Rolfs, B., Smith, D.G., Comparison of the frequencies of major histocompatibility (MHC) class-II DQA1 and DQB1 alleles in Indian and Chinese rhesus macaques. Comp. Med. 51 (2001), 555–561.
288. Volkow, N.D., et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am. J. Psychiatry 155 (1998), 1325–1331.
289. Volkow, N.D., et al. Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am. J. Psychiatry 158 (2001), 377–382.
290. Vu, L.T., et al. HLA-DR matching in organ allocation: balance between waiting time and rejection in pediatric kidney transplantation. JAMA Surg. 146 (2011), 824–829.
291. Wang, M., Jiang, L., Monticone, R.E., Lakatta, E.G., Proinflammation: the key to arterial aging. Trends Endocrinol. Metab. 25 (2014), 72–79.
292. Wang, S., et al. Autologous iPSC-derived dopamine neuron transplantation in a nonhuman primate Parkinson's disease model. Cell Discovery, 1, 2015, 15012.
293. Ward, J.M., Vallender, E.J., The resurgence and genetic implications of New World primates in biomedical research. Trends Genet. 28 (2012), 586–591.
294. Watkins, D.I., Zemmour, J., Parham, P., Non-human primate MHC class I sequences. Immunogenetics 37 (1993), 317–330.
295. Whone, A., et al. Slower progression of Parkinson's disease with ropinole versus levopdopa - the REAL-PET study. Ann. Neurol. 54 (2003), 93–101.
296. Wichmann, T., et al. Comparison of MPTP-induced changes in spontaneous neuronal discharge in the internal pallidal segment and in the substantia nigra pars reticulata in primates. Exp. Brain Res. 125 (1999), 397–409.
297. Willis, E.L., Wolf, R.F., White, G.L., McFarlane, D., Age- and gender-associated changes in the concentrations of serum TGF-1beta, DHEA-S and IGF-1 in healthy captive baboons (Papio hamadryas anubis). Gen. Comp. Endocrinol. 195 (2014), 21–27.
298. Wirdefeldt, K., Adami, H.O., Cole, P., Trichopoulos, D., Mandel, J., Epidemiology and etiology of Parkinson's disease: a review of the evidence. Eur. J. Epidemiol. 26:Suppl. 1 (2011), S1–58.
299. Wolf, R.F., et al. Baboon model for West Nile virus infection and vaccine evaluation. Virology 355 (2006), 44–51.
300. Wu, Y., et al. Nonhuman primate induced pluripotent stem cells in regenerative medicine. Stem Cells Int., 2012, 2012, 767195.
301. Xi, J., et al. Specification of midbrain dopamine neurons from primate pluripotent stem cells. Stem Cells 30 (2012), 1655–1663.
302. Xian, B., Huang, B., The immune response of stem cells in subretinal transplantation. Stem Cell Res. Ther., 6, 2015, 161.
303. Yuasa, S., Nakamura, K., Kohsaka, S., Stereotaxic Atlas of the Marmoset Brain with Immunohistochemical Architecture and MR Images. 2010, National Institute of Neuroscience, Tokyo.
304. Zhang, K., Sejnowski, T.J., A universal scaling law between gray matter and white matter of cerebral cortex. Proc. Natl. Acad. Sci. U. S. A. 97 (2000), 5621–5626.
305. Zhao, T., Zhang, Z.N., Rong, Z., Xu, Y., Immunogenicity of induced pluripotent stem cells. Nature 474 (2011), 212–215.
306. Zinner, D., Wertheimer, J., Liedigk, R., Groeneveld, L.F., Roos, C., Baboon phylogeny as inferred from complete mitochondrial genomes. Am. J. Phys. Anthr. 150 (2013), 133–140.
307. Zurcher, N.R., et al. Performance of juvenile baboons on neuropsychological tests assessing associative learning, motivation and attention. J. Neurosci. Methods 188 (2010), 219–225.